A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase

Jianbiao Zhou, Sabrina Hui-Min Toh, Zit-Liang Chan, Jessie Yiying Quah, Jing-Yuan Chooi, Tuan Zea Tan, Phyllis S.y. Chong, Qi Zeng, Wee Joo ChngJournal of Hematology & Oncology 2018 · DOI

TL;DR

Researchers have identified a novel synthetic lethal interaction in Acute Myeloid Leukemia (AML) cells that overexpress the PRL-3 phosphatase. By simultaneously inhibiting the AKT/mTOR and WNT/β-catenin signaling pathways, they achieved significant synergistic killing of these cancer cells, offering a promising new therapeutic strategy for a subset of AML patients with poor prognoses.

What Problem Does This Paper Address?

Acute Myeloid Leukemia (AML) is a diverse and aggressive blood cancer with a challenging 5-year survival rate. While protein tyrosine phosphatase of regenerating liver 3 (PRL-3) is known to be overexpressed in a significant portion of AML patients, particularly those with a worse prognosis, developing a direct inhibitor for PRL-3 has been difficult due to its shallow and hydrophobic active pocket. This limitation necessitates an indirect approach to target PRL-3, by identifying and exploiting pathways or molecules that cancer cells with high PRL-3 expression become dependent on for their survival. The paper aims to uncover these dependencies and explore their therapeutic potential.

Methods

The study employed a multi-pronged approach:

  • Genome-wide shRNA Library Screening: A pooled, whole-genome lentiviral shRNA library was used to screen for genes that, when knocked down, were synthetically lethal to AML cells overexpressing PRL-3. This was performed using isogenic cell lines (TF1-pEGFP as control and TF1-hPRL3 with PRL-3 overexpression).
  • Synthetic Lethality Validation: Small molecule inhibitors targeting the identified pathways were used to validate the synthetic lethal interactions in both cell lines and primary AML patient samples.
  • Cell Viability Assays: CellTiter-Glo® Luminescent Cell Viability Assay (CTG assay) was used to measure cell growth and viability under different treatment conditions.
  • Apoptosis Assays: Annexin V-FITC and propidium iodide (PI) staining followed by flow cytometry was used to quantify apoptotic cell populations.
  • Western Blot Analysis: This technique was used to assess the expression levels of key proteins involved in the targeted pathways and apoptosis.
  • In Vivo Xenograft Model: Human AML cells were xenografted into immunodeficient mice to evaluate the efficacy of the combination therapy in a living system, assessing survival and leukemic burden.
  • Quantitative Reverse Transcription PCR (qRT-PCR): Used to confirm PRL-3 expression levels in cell lines and patient samples.
  • Combination Index (CI) and Isobologram Analysis: CalcuSyn software was used to quantitatively assess the synergistic, additive, or antagonistic effects of drug combinations.

Datasets

The study utilized:

  • TCGA RNA-seq data: Publicly available RNA-seq data from The Cancer Genome Atlas (TCGA) cohort was used to analyze PRL-3 gene expression and its correlation with patient survival.
  • Human AML cell lines: Isogenic TF1-pEGFP and TF1-hPRL3 cell lines, along with MOLM-14 and OCI-AML2 cell lines.
  • Primary AML patient samples: Bone marrow blast cells from newly diagnosed AML patients were obtained and used for validation studies.
  • Mouse xenograft models: NOD/SCID mice were used to establish in vivo models of AML.

Key Insights and Ideas

  • PRL-3 as a Prognostic Factor: High expression of PRL-3 is confirmed as an independent prognostic factor for poor survival in AML patients, reinforcing its therapeutic relevance.
  • WNT/β-catenin and AKT/mTOR Dependency: AML cells with high PRL-3 expression exhibit a critical dependency on both the WNT/β-catenin and AKT/mTOR signaling pathways for their survival. This dependency is not as pronounced in PRL-3 low AML cells.
  • Synthetic Lethality Achieved: Simultaneous inhibition of AKT/mTOR (using VS-5584) and WNT/β-catenin (using ICG-001) pathways leads to a synergistic killing effect specifically in PRL-3 high AML cells.
  • Pathway Crosstalk: The findings suggest a cooperative signaling network between AKT/mTOR and WNT/β-catenin pathways that is essential for the survival of PRL-3 high AML cells.
  • Targeted Therapy Potential: This combinatorial approach offers a promising strategy to selectively target and eliminate PRL-3 high AML cells, potentially sparing normal cells.

Key Results

  • Genome-wide screen identified WNT/β-catenin and AKT/mTOR pathways: The shRNA screen revealed significant enrichment of genes involved in these pathways among the synthetic lethal targets of PRL-3 overexpressing cells.
  • Synergistic cell death: Combination treatment with VS-5584 and ICG-001 induced significantly higher apoptosis and cell death in MOLM-14 (PRL-3 high) cells compared to single-agent treatments. This was accompanied by increased caspase 3/7 activity and PARP cleavage.
  • PRL-3 level dictates synergy: The synergistic effect of the combination therapy was strongly associated with the level of PRL-3 expression. Primary AML samples with high PRL-3 showed synergistic killing, while those with low PRL-3 exhibited additive or antagonistic effects.
  • Improved survival in vivo: In AML xenograft mouse models, the combination therapy significantly prolonged survival and reduced leukemic burden in mice engrafted with PRL-3 high AML cells (MOLM-14) compared to single-agent treatments or vehicle control. This effect was not observed in mice engrafted with PRL-3 low AML cells (OCI-AML2).

Limitations and Future Work

  • Potential for shRNA pool representation issues: The authors acknowledge that using only a portion of DNA extracted from each shRNA pool for PCR and sequencing might pose challenges in representing the entire shRNA pool.
  • In vitro vs. in vivo differences: While the in vitro results were largely recapitulated in vivo, further validation in more complex models might be beneficial.
  • Broader applicability: The authors suggest that this combination therapy might be effective in other cancers that express high levels of PRL-3, but this requires further investigation.
  • Clinical Translation: The study strongly warrants further clinical investigation to evaluate the efficacy and safety of this combinatorial therapy in AML patients with high PRL-3 expression.

Summary updated

Abstract

In summary, our results support the existence of cooperative signaling networks between AKT/mTOR and WNT/β-catenin pathways in PRL-3 high AML cells. Simultaneous inhibition of these two pathways could achieve robust clinical efficacy for this subtype of AML patient with high PRL-3 expression and warrant further clinical investigation.
BibTeX
@article{zhou2018loss,
  author = {Jianbiao Zhou and Sabrina Hui-Min Toh and Zit-Liang Chan and Jessie Yiying Quah and Jing-Yuan Chooi and Tuan Zea Tan and Phyllis S.Y. Chong and Qi Zeng and Wee Joo Chng},
  title = {{A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase}},
  journal = {Journal of Hematology \& Oncology},
  year = {2018},
  doi = {10.1186/s13045-018-0581-9},
}
Figure